Search
Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB15514ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15517ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Kansas/14/2017 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15518ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/North carolina/04/2016 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15562ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15620ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15621ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Hawaii/70/2019 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15700ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15704ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15705ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15706ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.